Rani Therapeutics Holdings, Inc. (RANI) Stock Forecast
RANI analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $7.20 average of analyst targets
- Upside to target
- +1,023.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.05
- 52-week range
- $0.63 – $2.85
RANI analyst ratings
5 analystsNumber of analysts at each rating.
RANI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RANI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.05 | −$0.04 | −$0.12 | +61.1% | 3 |
| Current fiscal year (2026) | −$0.17 | −$0.18 | −$0.17 | −$0.45 | +61.5% | 3 |
| Next fiscal year (2027) | −$0.19 | −$0.20 | −$0.17 | −$0.17 | −9.6% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RANI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.3M | $0 | $1.7M | 0.0% | 4 |
| Current fiscal year (2026) | $6.3M | $3.4M | $8.0M | +283.2% | 4 |
| Next fiscal year (2027) | $6.6M | $0 | $18.0M | +6.0% | 4 |
RANI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RANI revenue: reported and forecast
RANI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.05 | −$0.05 | −$0.05 | −$0.05 | −15.1% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.20 | −$0.19 | −$0.18 | −$0.18 | −$0.17 | −15.5% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.23 | −$0.22 | −$0.21 | −$0.21 | −$0.19 | −17.4% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RANI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RANI beat in 9 of 12.
What analysts expect from RANI
5 analysts cover Rani Therapeutics; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.20, 1,023.2% above the latest close of $0.64. Analysts expect earnings of −$0.17 per share for 2026, +61.5% from a year earlier. For 2027 the average estimate is −$0.19 per share on revenue of $6.6 million. Rani Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: RANI income statement, RANI key metrics, RANI chart. See the RANI stock overview for the latest quote and news.
RANI forecast FAQ
What is Rani Therapeutics's price target?
The average analyst price target for Rani Therapeutics is $7.20, 1,023.2% above the latest close of $0.64.
Is Rani Therapeutics a buy, hold or sell?
Of 5 analysts covering Rani Therapeutics, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Rani Therapeutics's EPS forecast?
Analysts forecast −$0.17 per share for 2026 (range −$0.18 to −$0.17); for 2027 the estimate is −$0.19.
What is Rani Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $6.3 million, growth of 283.2%; for 2027 it is $6.6 million.
When does Rani Therapeutics report earnings?
Rani Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.05.
Does Rani Therapeutics usually beat earnings estimates?
Rani Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.